RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0034-1394377
Positronenemissionstomografische Diagnostik kindlicher Sarkome
Positron Emission Tomography in the Diagnosis of Sarcomas in Childhood and AdolescencePublikationsverlauf
Publikationsdatum:
24. November 2014 (online)
Zusammenfassung
Bei den Sarkomen des Kindesalters handelt es sich um eine heterogene Gruppe von Tumoren, für die wenige allgemeingültige Aussagen getroffen werden können. Für Ewing-Sarkome und Rhabdomyosarkome ist die FDG-PET ein exzellentes Instrument zur Primärtumor-Suche und für den Nachweis von Weichteil- oder Knochenmetastasen. In Verbindung mit der CT, die Lungenmetastasen mit höchster Sensitivität zeigt, kann die PET/CT für das Staging gut eingesetzt werden. Für die Operationsplanung wird in der Regel jedoch der MRT der Vorzug zu geben.
Die Metastasen von Osteosarkomen verhalten sich demgegenüber anders, und sind in der Regel in Skelett-Szintigrafie, CT und MRT besser zu diagnostizieren.
Die PET/CT sollte wo immer möglich im Rahmen klinischer Studien systematisch evaluiert werden.
Abstract
Paediatric sarcomas are a heterogeneous group of tumors, for which few generally accepted statements can be made. In Ewing sarcomas and Rhabdomyosarcomas FDG-PET is an excellent instrument to assess metabolic activity of the primary tumors and to identifying nodal and soft tissue metastases or metastastic bone involvement. In combination with CT, which shows pulmonary metastases with the highest sensitivity, PET/CT can be applied optimally for staging. However, MRI still remains superior for planning surgery. In contrast, metastases of osteosarcomas behave differently and bone scintigraphy, CT and MRI are in most cases sufficient for staging. PET/CT should be systematically evaluated in clinical studies whenever possible.
-
Literatur
- 1 Baum SH, Fruhwald M, Rahbar K et al. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med 2011; 52: 1535-1540
- 2 Byun BH, Kong CB, Lim I et al. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential F-FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging 2014;
- 3 Denecke T, Hundsdorfer P, Misch D et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 2010; 37: 1842-1853
- 4 Dharmarajan KV, Wexler LH, Gavane S et al. Positron emission tomography (PET evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2012; 84: 996-1002
- 5 Eugene T, Corradini N, Carlier T et al. (18)F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun 2012; 33: 1089-1095
- 6 Federico SM, Spunt SL, Krasin MJ et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer 2013; 60: 1128-1134
- 7 Franzius C, Bielack S, Flege S et al. Prognostic significance of (18)F-FDG and (99 m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002; 43: 1012-1017
- 8 Gerth HU, Juergens KU, Dirksen U et al. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007; 48: 1932-1939
- 9 Gupta K, Pawaskar A, Basu S et al. Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin Nucl Med 2011; 36: 973-977
- 10 Hawkins DS, Conrad EU, Butrynski JE et al. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009; 115: 3519-3525
- 11 Juergens KU, Weckesser M, Stegger L et al. Tumor staging using whole-body high-resolution 16-channel PET-CT: does additional low-dose chest CT in inspiration improve the detection of solitary pulmonary nodules?. Eur Radiol. 2006. 16. 1131-1137
- 12 Jürgens H, Paulussen M, Zoubek A. Ewing-Tumoren. In: Gadner H, Gaedicke G, Niemeyer Ch, Ritter J. (eds.) Pädiatrische Hämatologie und Onkologie. Springer-Verlag; 2006
- 13 Kaatsch PSC. German Childhood Cancer Registry – Report 2012 (1980–2012). Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI at the University Medical Center of the Johannes Gutenberg University Mainz 2013;
- 14 Klem ML, Grewal RK, Wexler LH et al. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007; 29: 9-14
- 15 Lisle JW, Eary JF, O’Sullivan J et al. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin Orthop Relat Res 2009; 467: 1605-1611
- 16 Newman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer 2013; 60: 1113-1117
- 17 Quartuccio N, Treglia G, Salsano M et al. The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol 2013; 47: 97-102
- 18 Ricard F, Cimarelli S, Deshayes E et al. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 2011; 36: 672-677
- 19 Sharma P, Khangembam BC, Suman KC et al. Diagnostic accuracy of 18 F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma. Eur J Nucl Med Mol Imaging 2013; 40: 1036-1043
- 20 Tateishi U, Hosono A, Makimoto A et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009; 23: 155-161
- 21 Treuner J, Brecht IB. Weichteilsarkome. In: Gadner H, Gaedicke G, Niemeyer Ch, Ritter J. eds. Springer-Verlag; 2006
- 22 Tsai LL, Drubach L, Fahey F et al. [18 F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol 2012; 108: 469-475
- 23 Ulaner GA, Magnan H, Healey JH et al. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18 F-FDG PET/CT is performed?. AJR Am J Roentgenol 2014; 202: 859-867
- 24 Volker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25: 5435-5441
- 25 Vrachimis A, Dirksen U, Wessling J et al. PET surveillance of patients with Ewing sarcomas of the trunk: Must the lower legs be included?. Nuklearmedizin 2010; 49: 183-186